Abstract
Introduction

Patients with slowly progressive type 1 diabetes (1) (SPT 1D) or latent autoimmune diabetes in adults (LADA) (2) are characterized as non-insulin dependent at the onset of diabetes, are positive for β cell antibody(ies), and become insulin dependent after a few years. Although the Tokyo Study showed that low-dose insulin injections prevent or delay the decline of insulin secretion in SPT1D patients
 (3) 
minute), 177 mg/dL (30 minutes), 232 mg/dL (60 minutes), 236 mg/dL (90 minutes), 234 mg/dL (120 minutes), and Cpeptide values were 1.43 ng/mL (0 minutes), 2.78 ng/mL (30 minutes), 4.74 ng/mL (60 minutes), 6.84 ng/mL (90 minutes), 8.79 ng/mL (120 minutes).
His human leukocyte antigen (HLA) type was A310102, A110101, B150101, B670101, C030301, C070201, DRB1 150101, DRB1 160201, DQB1 050201, DQB1 0602.
Abbreviation: GAD: glutamic acid decarboxylase
Discussion
Recently, Maruyama et al showed that a low dose of insulin administration prevented or delayed insulin deficiencies in SPT1D patients (3). This intervention was most beneficial in patients with both a high titer of GADA (over 10 U/mL) and preserved insulin secretion, i. !. ΣC-peptide over 10 ng/ mL. Based on their hypothesis, we recommended insulin administration for the present patient, but he chose the treatment with oral hypoglycemic agent. Thiazolidinediones are peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists. PPAR-γ is a ligand-activated nuclear receptor and controls the expression of metabolic and immune response genes including nuclear factor (NF)-κB. Trans-repression of NF-κB leads to low interferon (IFN)-γ expression, and prevents T-helper1 (Th1) skewing of the Th1/Th2 balance (5). In fact, troglitazone was shown to ameliorate experimental autoimmune encephalomyelitis,
which is thought to be a Th1 disease (6) .
Of (8) . These findings were further confirmed by other groups (9, 10) and another thiazolidinedione was also reported to prevent the type 1 diabetes (11, 12) . It was proposed that thiazolidinediones might be considered for β cell protection in LADA patients (12) . In humans, Zhou et al (13) 
